Lack of antiviral activity of darunavir against SARS-CoV-2
- Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM). Conclusions: Overall, the data do not support the use of DRV for the treatment of COVID-19.
Author: | Sandra De MeyerORCiD, Denisa BojkovaORCiDGND, Jindrich CinatlORCiDGND, Ellen van DammeORCiD, Christophe BuyckORCiD, Marnix van LoockORCiD, Brian Woodfall, Sandra CiesekORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-549606 |
DOI: | https://doi.org/10.1016/j.ijid.2020.05.085 |
ISSN: | 1878-3511 |
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/32479865 |
Parent Title (English): | International Journal of Infectious Diseases |
Publisher: | Elsevier |
Place of publication: | Amsterdam [u.a.] |
Document Type: | Article |
Language: | English |
Year of Completion: | 2020 |
Date of first Publication: | 2020/05/29 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2020/06/15 |
Tag: | COVID-19; Darunavir; In vitro; SARS-CoV-2 |
Volume: | 97 |
Page Number: | 4 |
First Page: | 7 |
Last Page: | 10 |
Note: | © 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
HeBIS-PPN: | 467138656 |
Institutes: | Medizin / Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | Creative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0 |